Sustained symptom reduction in complex regional pain syndrome with a novel home-based virtual reality program: a pilot study

一项基于家庭的新型虚拟现实程序可持续减轻复杂区域疼痛综合征的症状:一项试点研究

阅读:3

Abstract

BACKGROUND: Complex regional pain syndrome (CRPS) often leads to limb disuse, pain catastrophizing, and depression. While physical movement of CRPS affected limbs is essential for improvement, pain discourages movement. Home-based virtual reality (VR) interventions may reduce movement-related pain, improve adherence, and promote sustained symptom reduction. METHODS: In this exploratory pilot study, seven patients with CRPS completed a 4-month home-based VR program integrating three treatment modules (1) embodied cyberhands VR physical movement treatment, (2) VR-mindfulness-based-stress-reduction, and (3) VR-pain-neuroscience-education. The primary outcomes were patient-reported global impressions of change in CRPS-related pain and physical ability. Secondary outcomes included central sensitization, cold sensitivity, depression, pain catastrophizing, and upper-limb function. RESULTS: On the primary outcome global impression of change measures, six of seven patients reported sustained improvement in CRPS-related pain and physical ability, with three reporting being "much" or "very much" improved at 4 months. Gains were maintained at 1-year follow-up. Secondary outcomes showed significant improvements at 4 months: central sensitization (CSI: 46.7 ± 11.97 to 38.4 ± 11.53), cold pain threshold (27.12 °C ± 3.89 to 24.56 °C ± 5.56), depression (CES-D: 23.0 ± 11.27 to 15.6 ± 8.85), pain catastrophizing (PCS: 24.3 ± 11.06 to 15.1 ± 9.67), and upper-limb function (QuickDASH: 47.7 ± 20.43 to 34.8 ± 17.47). Improvements were sustained at 1-year follow-up. No serious adverse events occurred, and study adherence was 100%. CONCLUSION: Results provide preliminary evidence that a home-based VR program may produce sustained improvements in CRPS-related pain, physical ability, and associated symptoms. Larger randomized controlled trials are recommended. CLINICAL TRIAL REGISTRATION: The study was registered on September 21, 2024, with the identifier number NCT05888142.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。